Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

被引:98
|
作者
Norman, Jill [1 ]
机构
[1] UCL Med Sch, Div Med, UCL Ctr Nephrol, London NW3 2PF, England
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2011年 / 1812卷 / 10期
关键词
Fibroblasts; Myofibroblasts; Fibrosis; Extracellular matrix; Epithelial-fibroblast interactions; Chronic kidney disease; ABNORMAL EXTRACELLULAR-MATRIX; GELATINASE-A MMP-2; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; PKD1; GENE; INTERSTITIAL FIBROSIS; TARGETED DISRUPTION; TISSUE INHIBITOR; EPITHELIAL-CELLS; RENAL FIBROSIS;
D O I
10.1016/j.bbadis.2011.06.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The age on onset of decline in renal function and end-stage renal disease (ESRD) in autosomal polycystic kidney disease (ADPKD) is highly variable and there are currently no prognostic tools to identify patients who will progress rapidly to ESRD. In ADPKD, expansion of cysts and loss of renal function are associated with progressive fibrosis. Similar to the correlation between tubulointerstitial fibrosis and progression of chronic kidney disease (CKD), in ADPKD, fibrosis has been identified as the most significant manifestation associated with an increased rate of progression to ESRD. Fibrosis in CKD has been studied extensively. In contrast, little is known about the mechanisms underlying progressive scarring in ADPKD although some commonality may be anticipated. Current data suggest that fibrosis associated with ADPKD shares at least some of the "classical" features of fibrosis in CKD (increased interstitial collagens, changes in matrix metalloproteinases (MMPs), over-expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), over-expression of plasminogen activator inhibitor-1 (PAI-1) and increased transforming growth factor beta (TGF beta) but that there are also some unique and stage-specific features. Epithelial changes appear to precede and to drive interstitial changes leading to the proposal that development of fibrosis in ADPKD is biphasic with alterations in cystic epithelia precipitating changes in interstitial fibroblasts and that reciprocal interactions between these cell types drives progressive accumulation of extracellular matrix (ECM). Since fibrosis is a major component of ADPKD it follows that preventing or slowing fibrosis should retard disease progression with obvious therapeutic benefits. The development of effective anti-fibrotic strategies in ADPKD is dependent on understanding the precise mechanisms underlying initiation and progression of fibrosis in ADPKD and the role of the intrinsic genetic defect in these processes. This article is part of a Special Issue entitled: Polycystic Kidney Disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1327 / 1336
页数:10
相关论文
共 50 条
  • [1] Myofibroblast depletion reduces kidney cyst growth and fibrosis in autosomal dominant polycystic kidney disease
    Dwivedi, Nidhi
    Jamadar, Abeda
    Mathew, Sijo
    Fields, Timothy A.
    Rao, Reena
    KIDNEY INTERNATIONAL, 2023, 103 (01) : 144 - 155
  • [2] Role of apoptosis in the development of autosomal dominant polycystic kidney disease (ADPKD)
    Peintner, Lukas
    Borner, Christoph
    CELL AND TISSUE RESEARCH, 2017, 369 (01) : 27 - 39
  • [3] Changing Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Ruff, Suzanne F.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (07): : 934 - 935
  • [4] No association of the TGF-β1 gene polymorphisms with the renal progression in autosomal dominant polycystic kidney disease (ADPKD) patients
    Lee, JG
    Ahn, C
    Yoon, SC
    Park, JH
    Eo, HS
    No, JJ
    Kim, KH
    Lee, EJ
    Hwang, YH
    Hwang, DY
    Kim, YS
    Han, JS
    Kim, S
    Lee, JS
    Kim, SH
    CLINICAL NEPHROLOGY, 2003, 59 (01) : 10 - 16
  • [5] Hereditary cystic kidney diseases: autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD)
    Haumann, Sophie
    Burgmaier, Kathrin
    Bergmann, Carsten
    Mueller, Roman Ulrich
    Liebau, Max C.
    MEDIZINISCHE GENETIK, 2018, 30 (04): : 422 - 428
  • [6] Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression
    Furlano, Monica
    Loscos, Irene
    Marti, Teresa
    Bullich, Gemma
    Ayasreh, Nadia
    Rius, Asuncion
    Roca, Lourdes
    Ballarin, Jose
    Ars, Elisabet
    Torra, Roser
    AMERICAN JOURNAL OF NEPHROLOGY, 2018, 48 (04) : 308 - 317
  • [7] The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease
    Fragiadaki, Maria
    Macleod, Fiona M.
    Ong, Albert C. M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 15
  • [8] Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
    Zubidat, Dalia
    Hanna, Christian
    Randhawa, Amarjyot K.
    Smith, Byron H.
    Chedid, Maroun
    Kaidbay, Daniel-Hasan N.
    Nardelli, Luca
    Mkhaimer, Iraman G.
    Neal, Reem M.
    Madsen, Charles D.
    Senum, Sarah R.
    Gregory, Adriana V.
    Kline, Timothy L.
    Zoghby, Ziad M.
    Broski, Stephen M.
    Issa, Naim S.
    Harris, Peter C.
    Torres, Vicente E.
    Sfeir, Jad G.
    Chebib, Fouad T.
    BONE REPORTS, 2023, 18
  • [9] Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges
    McBride, Lucy
    Wilkinson, Catherine
    Jesudason, Shilpanjali
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2020, 12 : 409 - 422
  • [10] Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Sekine, Akinari
    Hidaka, Sumi
    Moriyama, Tomofumi
    Shikida, Yasuto
    Shimazu, Keiji
    Ishikawa, Eiji
    Uchiyama, Kiyotaka
    Kataoka, Hiroshi
    Kawano, Haruna
    Kurashige, Mahiro
    Sato, Mai
    Suwabe, Tatsuya
    Nakatani, Shinya
    Otsuka, Tadashi
    Kai, Hirayasu
    Katayama, Kan
    Makabe, Shiho
    Manabe, Shun
    Shimabukuro, Wataru
    Nakanishi, Koichi
    Nishio, Saori
    Hattanda, Fumihiko
    Hanaoka, Kazushige
    Miura, Kenichiro
    Hayashi, Hiroki
    Hoshino, Junichi
    Tsuchiya, Ken
    Mochizuki, Toshio
    Horie, Shigeo
    Narita, Ichiei
    Muto, Satoru
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)